NEA 14 Gp, Ltd., 10% Owner at Adaptimmune Therapeutics PLC (ADAP), bought 2,537,016 shares at $1.81 ($4.8M) on 2018-03-21, disclosed to the SEC on 2018-03-23.
Open-market purchase of $4.8M ADAP by 10% Owner. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history).
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $1.81 | 104,844 | $190K | 3.9% |
| 2 | $1.81 | 104,844 | $190K | 3.9% |
| 3 | $1.90 | 869,574 | $1.7M | 34.2% |
| 4 | $1.90 | 869,574 | $1.7M | 34.2% |
| 5 | $1.95 | 294,090 | $573K | 11.9% |
| 6 | $1.95 | 294,090 |
| $573K |
| 11.9% |
| Total | $1.90 avg | 2,537,016 | $4.8M | 100% |
| Filing → |
| TCON | BUY | 2018-03-27 | $3.8M | — | Filing → |
| MRSN | BUY | 2017-07-06 | $15.0M | — | Filing → |
| ADAP | BUY | 2017-03-28 | $9.0M | — | Filing → |